From GlobeNewswire:

Olema Pharmaceuticals, Inc. has granted stock options to four new employees to purchase an aggregate of 33,600 shares of the Company’s common stock, effective as of February 1, 2024. The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company’s 2022 Inducement Plan.

The stock options have a 10-year term and an exercise price of $15.25 per share, equal to the last reported sale price of the Company’s common stock as reported by Nasdaq on February 1, 2024. Olema is a biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. For more information, please visit them at www.olema.com.



Read more: Olema Oncology Reports Inducement Grants Under Nasdaq